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Summary
 
A peptide derived from the human papillomavirus L2 protein is recognized by a myelin basic
protein (MBP)-specific T cell clone from a multiple sclerosis patient and by MBP-specific au-
toantibodies purified from multiple sclerosis brain tissue. We now show in mice that low doses
of this papillomavirus peptide were optimal in selecting a subpopulation of papillomavirus pep-
tide–specific T cells that cross-reacted with MBP(87–99) and with an unrelated viral peptide
derived from the BSLF1 protein of Epstein-Barr virus (EBV). These low dose viral peptide–
specific T cell lines were highly encephalitogenic. Splenocytes from mice transferred with viral
peptide–specific T cells showed a vigorous response to both the papillomavirus and MBP pep-
tides, indicating that viral antigen–specific T cells survived for a prolonged time in vivo. The
EBV peptide, unable to prime and select an autoreactive T cell population, could still activate
the low dose papillomavirus peptide–specific cells and induce central nervous system (CNS)
autoimmunity. Cytokine profiles of papillomavirus peptide–specific encephalitogenic T cells
and histopathology of CNS lesions resembled those induced by MBP. These results demon-
strate conserved aspects in the recognition of the self-antigen and a cross-reactive viral peptide
by human and murine MBP-specific T cell receptors. We demonstrate that a viral antigen, de-
pending on its nature, dose, and number of exposures, may select autoantigen-specific T cells
that survive in vivo and can trigger autoimmune disease after adoptive transfer.
Key words: autoimmunity • cross-reactivity • experimental autoimmune encephalomyelitis • 
molecular mimicry • antigenic peptide
utoimmunity has been proposed as the pathogenetic
basis for a large number of organ-specific and systemic
diseases of unknown etiology. Based on epidemiological
studies, it is thought that autoimmunity results from inher-
itance of susceptibility genes (1–3), as well as environmen-
tal factors that play a role in regulating the expression of
these genetic traits (for reviews, see references 4–6). For an
autoimmune process to occur, self-reactive cells that have
escaped thymic deletion have to be activated and ex-
panded. Peptides and superantigens derived from infectious
agents are potent activators of T cell–dependent immune
responses. For this reason, infectious agents have been sus-
pected for decades to be environmental triggers of autoim-
munity. Epidemiological studies, mainly geographic distri-
bution and migration studies (for reviews, see references 5
and 7) and concordance studies between monozygotic and
dizygotic twins (8, 9), provide indirect support for this hy-
pothesis. This hypothesis is also supported by several studies
in transgenic animal models. Myelin basic protein (MBP)
 
1
 
-
specific TCR transgenic mice developed spontaneous central
nervous system (CNS) autoimmunity with a significantly
higher incidence when the animals were not housed under
specific pathogen–free conditions (10). Also, transgenic
mice that expressed a viral antigen as a “self”-antigen in is-
let cells of the pancreas developed diabetes when infected
with the respective virus (11, 12). Several mechanisms
could account for a role of infections in the etiology of au-
toimmune diseases. These include autosensitization due to
tissue injury in the target organ (13–15), T cell activation
 
1
 
Abbreviations used in this paper:
 
 CNS, central nervous system; EAE, exper-
imental autoimmune encephalomyelitis; H&E, hematoxylin and eosin;
MBP, myelin basic protein; MS, multiple sclerosis; SEA, Staphylococcal
enterotoxin A.
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by microbial superantigens (16), and T cell activation by
cross-reactive microbial peptides (6, 17–19).
Structural similarities between microbial and self-pep-
tides can result in the activation of autoreactive T cells; this
concept has been referred to as “molecular mimicry.” In
some instances, structural similarities can be identified by
sequence alignment between a self-peptide and microbial
antigens. This approach has been used to identify microbial
peptides that induce histological and/or clinical signs of dis-
ease in several animal models, such as experimental autoim-
mune encephalomyelitis (EAE) in rabbits and autoimmune
oophoritis or streptococcal myocarditis in mice (17, 20, 21).
In a recent paper, Zhao et al. (22) demonstrated that an
epitope expressed by a coat protein of HSV-1 could be rec-
ognized by autoreactive T cells that target corneal antigens
in a murine model of autoimmune herpes stromal keratitis.
Mutant HSV-1 viruses that lacked this epitope did not in-
duce autoimmune disease. In the herpes stromal keratitis
model, the presence of the virus at the site of autoimmune
inflammation was required.
Analysis of the structural requirements for MHC class II
binding and TCR recognition by MBP(85–99)-specific T
cell clones derived from multiple sclerosis (MS) patients re-
vealed that several peptides, including peptides from viral
and bacterial origin, that had limited sequence homology
with the MBP peptide or to each other could activate the
same T cell clone (19, 23–25). For one of these viruses it
was possible to demonstrate that a naturally processed viral
peptide could also activate MBP-specific T cells (19). In
addition, microbial peptides were identified that were
bound by affinity-purified MBP-specific autoantibodies
from CNS tissue of MS cases. Due to similarities in the T
cell and B cell epitopes of MBP, a papillomavirus peptide
was identified that was recognized by an MBP-specific T
cell clone and by autoantibodies (26, 27). Although studies
with individual T cell clones are essential in furthering our
understanding of the structural basis of molecular mimicry,
it is important to consider the existence in vivo of a multi-
tude of TCRs that can interact with multiple antigens. It is
then crucial to investigate the induction of autoimmune
disease by viral antigens in an animal model in which the
dynamics of polyclonal T cell populations play a major
role.
EAE in mice is a well-established model of autoimmune
disease that provides an appropriate system to address these
questions in vivo (28–31). EAE can be induced either by
passive transfer of myelin antigen–specific T cells, or by
subcutaneous immunization with a myelin antigen in adju-
vant (32–34). It has been shown that even a six-residue
peptide, from which five amino acids were derived from
the NH
 
2
 
-terminal region of native MBP, could induce
EAE in susceptible mice (35). However, the importance of
the NH
 
2
 
-terminal acetylation for the encephalitogenicity
of MBP(Ac1-11) in the PL mouse has made it difficult to
identify cross-reactive microbial peptides in that model.
We chose to study the SJL mouse model in which the
MBP(87–99) peptide is both immunodominant and en-
cephalitogenic (36); this peptide is also immunodominant
for human T cells (37–39), potentially allowing analysis of
microbial peptides that activate human T cell clones.
In this study, three viral peptides were identified that ac-
tivated LN T cells from MBP(87–99)-primed SJL mice. T
cells specific for a papillomavirus peptide induced severe
EAE after adoptive transfer and could be isolated from
mice 
 
.
 
11 wk after transfer. In this model, the viral antigen
was not present in the target organ, ruling out inflamma-
tion mediated by viral peptide–specific T cells activated lo-
cally by the same viral peptide. Interestingly, we found that
low doses of the papillomavirus peptide (0.004–0.4 
 
m
 
g/ml)
were superior to moderate or high doses (10–80 
 
m
 
g/ml) in
selecting a subpopulation of viral peptide–specific T cells in
vitro that cross-reacted with MBP(87–99) and also with an
EBV peptide. In vitro reactivation of papillomavirus-spe-
cific T cells by this EBV peptide also resulted in EAE after
adoptive transfer. Pathological examination demonstrated
that viral peptide–induced disease was indistinguishable
from EAE triggered by the self-antigen. The relevance of
these results for the induction of autoimmunity by molecu-
lar mimicry is discussed.
 
Materials and Methods
 
Mice.
 
Female SJL mice were obtained from The Jackson Lab-
oratory (Bar Harbor, ME) and from the Frederick Cancer Re-
search and Development Center (Frederick, MD). All mice were
kept under specific pathogen–free conditions at the animal facili-
ties of the National Institutes of Health and were used between 7
and 12 wk of age according to approved protocols.
 
Antigens.
 
MBP was prepared from guinea pig spinal cords
(Harlan Sprague Dawley Inc., Indianapolis, IN) according to the
protocol from Deibler et al. (40). The peptides used in screening
for cross-reactivity to the peptide MBP(87–99) (see Table 1)
were synthesized by Quality Controlled Biochemicals, Inc.
(Hopkinton, MA) and by Chiron Mimotopes (San Diego, CA).
MBP(87–99), MBP(83–100), papillomavirus peptide (pHPV-7),
and EBV peptide (pEBV) were prepared by continuous flow solid
phase synthesis by the Protein and Nucleic Acid Facility, Beck-
man Center, Stanford University (Stanford, CA). The peptide
NP(260–283) was a gift from Drs. Benjamin Segal and Ethan
Shevach (National Institute of Allergy and Infectious Diseases,
Bethesda, MD).
 
Cloning.
 
T
 
 
 
cell clones were generated by limiting dilution.
LN cells from mice that had been immunized with 200 
 
m
 
g of the
papillomavirus peptide pHPV-7 were stimulated twice in vitro
with low doses (0.01–0.05 
 
m
 
g/ml) of the priming antigen. At the
third in vitro stimulation, T cells were seeded at 0.5 cells/well to-
gether with 3 
 
3 
 
10
 
5
 
 irradiated splenocytes/well and antigen (pap-
illomavirus peptide) in 96-well round-bottomed plates. On days
4, 7, and 10 after stimulation, the medium was changed for EAE
medium containing 10% of medium from Con A–stimulated
splenocytes. At day 14, the cells were restimulated using the same
dose of antigen and number of APCs as before. The cycle of re-
stimulation was repeated until cells were expanded (the typical
cloning efficiency resulted in clonal growth in 
 
,
 
1/60 wells seeded).
 
Induction of EAE by Passive Transfer.
 
An emulsion, containing
equal volumes of CFA (Difco Laboratories, Inc., Detroit, MI)
and a solution of antigen in PBS, was used to immunize mice
subcutaneously. 200 
 
m
 
l of the emulsion was distributed over four
sites at the flanks of the animals. A total of 400 
 
m
 
g of MBP, 200 
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g of peptide (MBP(87–99), pHPV-7, pEBV), or just PBS in
CFA (referred to as CFA immunization) was injected per mouse.
For the influenza nucleoprotein peptide NP(260–283), only 5
 
m
 
g/mouse was used (optimal dose [41]). The draining LNs were
removed 10 d after the immunization, and the cells were stimu-
lated in vitro using the immunizing antigen, a cross-reactive anti-
gen, or an irrelevant antigen. For the stimulation, 2 ml of a sus-
pension of 4 
 
3 
 
10
 
6
 
 cells/ml in EAE medium (RPMI 1640
[GIBCO BRL, Gaithersburg, MD] supplemented with 2 mM
glutamine, 10 mM Hepes, 100 U/ml penicillin, 100 
 
m
 
g/ml strep-
tomycin, 0.1 mM nonessential amino acids, 1 mM sodium pyru-
vate [all from BioWhittaker, Inc., Walkersville, MD], and 10%
fetal bovine serum [GIBCO BRL]) was placed in each well of
24-well plates (Costar Corp., Cambridge, MA) with the appro-
priate concentration of antigen. Supernatants from representative
wells were collected for cytokine analysis at 48, 72, and 96 h. 4 d
after stimulation, the cells were collected and were either trans-
ferred into naive recipients or kept for further experiments.
When transferred at this stage, the cells were washed once in EAE
medium and once in PBS, and 0.6–1 
 
3 
 
10
 
8
 
 cells were injected
intraperitoneally into each recipient mouse. Alternatively, the
cells were cultured in 80-cm
 
2
 
 flasks. 13–14 d after the first in vitro
activation, they were washed and restimulated. For the stimula-
tion of T cell lines, a suspension containing 10
 
6
 
 T cells/ml, 3 
 
3
 
10
 
6
 
 irradiated (3,000 rads) splenocytes per ml, and the appropriate
concentration of antigen was distributed into 24-well plates (2
ml/well). Supernatants were collected at different time points to
measure the concentrations of cytokines. When transferred after
two or more rounds of stimulation, the cells were collected and
washed at 72 h and injected intraperitoneally into naive recipi-
ents.
 
Clinical Scores.
 
The clinical signs of EAE were scored using the
following scale: 0, no apparent abnormalities; 0.5, weak tail with
some muscle tone remaining; 1, completely limp tail; 1.5, hind leg
weakness as demonstrated by impaired righting ability and partially
limp tail; 2, impaired righting reflex with completely limp tail; 2.5,
hind leg weakness to the degree of short lapses of dragging of a leg;
3, complete hind leg paralysis; 4, complete hind leg paralysis and
weakness of front legs; 5, moribund (dead mice were scored as 5 if
they had previously shown signs of progressive disease).
 
Purification of T Cells.
 
In some cases (see Table 2), LN cells
were enriched for T cells to levels of 
 
.
 
97% purity by passing
them through mouse T cell enrichment columns (R&D Systems,
Minneapolis, MN) following the manufacturer’s instructions.
The recovered cells were washed twice and resuspended (10
 
6
 
cells/ml) in EAE medium together with irradiated splenocytes
(3 
 
3 
 
10
 
6
 
 cells/ml) and the appropriate concentration of antigen.
The suspension was plated in 24-well plates (2 ml/well).
 
In Vitro Proliferation Assays.
 
When LN cells were tested, 4 
 
3
 
10
 
5
 
 cells/well (0.2 ml) were cultured for 4 d in triplicates in 96-
well flat-bottomed plates (Costar Corp.) in the presence of vari-
ous concentrations of antigen or medium alone. In the case of T
cell lines, 2 
 
3 
 
10
 
4
 
 T cells and 2 
 
3 
 
10
 
5
 
 irradiated (3,000 rads) sple-
nocytes were cultured per well in round-bottomed plates (Nunc,
Inc., Roskilde, Denmark) for 3 d. In both cases, [
 
3
 
H]thymidine (1
 
m
 
Ci/well) was added for the last 6–12 h of culture. The incorpo-
ration of [
 
3
 
H]thymidine was determined in a scintillation counter
(1205 Betaplate; Wallac, Gaithersburg, MD) as described previ-
ously (34). Assays were performed in EAE medium, except for
those represented in Table 1, Fig. 1, and Fig. 7, 
 
A2
 
, 
 
B2
 
, and 
 
C2
 
,
for which serum-free lymphocyte culture medium (AIM-V
[GIBCO BRL] supplemented with 2 mM glutamine, 10 mM
Hepes, 100 U/ml penicillin, 100 
 
m
 
g/ml streptomycin, 0.1 mM
nonessential amino acids, and 1 mM sodium pyruvate) was used
in order to reduce background responses. The results were always
confirmed using EAE medium.
 
ELISA.
 
TNF-
 
a
 
, IFN-
 
g
 
, IL-4, and IL-10 were measured us-
ing a sandwich ELISA technique. DuoSet ELISA Development
System kits (Genzyme Corp., Cambridge, MA) were used for the
quantification of TNF-
 
a
 
, IFN-
 
g
 
, and IL-4, following the manu-
facturer’s recommendations. The antibodies for the detection of
IL-10 and the recombinant cytokine were obtained from Phar-
Mingen (San Diego, CA). The plates were developed with the
peroxidase substrate tetramethylbenzidine (TMB), stopped with
1 M sulfuric acid, and read at 450 nm using a microplate reader
(model MRX; Dynatech Laboratories, Inc., Chantilly, VA).
 
Histopathology.
 
Animals were killed by intracardiac perfusion
with PBS under narcosis at various stages of disease (10–96 d after
transfer). The brains and spinal cords were removed, fixed by im-
mersion in 10% phosphate-buffered formalin, and paraffin em-
bedded. Three longitudinal sections spanning the entire length of
the spinal cord, three cross-sections at different levels in the spinal
cord, and four to five sections of brain and brain stem were
stained with hematoxylin and eosin (H&E) for each animal. The
same number of sections (from adjacent 7-
 
m
 
m sections) were
stained with luxol fast blue. Sections were analyzed by a neuro-
pathologist who was not informed of the identity of the speci-
mens. Animals 1, 4, 10, 12, and 16 from Table 2 and three ani-
mals transferred with MBP(87–99)-specific short-term T cell lines
were examined.
 
Results
 
Identification of Pathogen-derived Peptides that Activate
MBP(87–99)-specific T Cells In Vitro.
 
The MBP(87–99)
peptide that is presented by the MHC class II molecule
I-A
 
s
 
 is an immunodominant MBP epitope in SJL mice. A
panel of microbial peptides with sequence similarity to this
MBP peptide was tested for the ability to activate LN T
cells from SJL mice primed with MBP(87–99). The fol-
lowing peptides were used (Table 1): group 1, peptides that
matched the recognition motif for human MBP(85–99)-
specific T cell clones (peptides pHPV-7, 19, 29, 34, 41, 43,
52, 70, 140, 149, 180, 186, and 193; reference 19); and
group 2, peptides that matched the recognition motif for
MBP(85–99)-specific autoantibodies from MS patients
(peptides B2–B23; reference 27); and group 3, peptides that
matched the T cell recognition motif for MBP(88–102)-
specific T cells from Lewis rats
 
 
 
(none of the 42 peptides in
this group showed cross-reactivity; data not included).
These peptides were tested in a proliferation assay using
LN cells derived from SJL mice immunized with MBP(87–
99). Three peptides were identified which activated
MBP(87–99)-specific T cells with a stimulation index 
 
.
 
10
(Table 1). These peptides were derived from the L2 minor
capsid protein of human papillomavirus type 7 (peptide
pHPV-7), the BSLF1 primase of EBV (peptide pEBV), and
the UL70 protein of human cytomegalovirus (peptide
pCMV). Three other peptides gave a stimulation index 
 
.
 
4
and were derived from human adenovirus (peptide B13),
 
Clostridium cellulare
 
 (peptide B18), and 
 
Vibrio anguillarum
 
(peptide B19). The papillomavirus peptide shares 6 of 17
amino acids with MBP(83–100), whereas the EBV peptide 
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shares 5 residues with the MBP peptide. Several peptides
(B2, B3, and B4) that also share five to six amino acids with
the MBP peptide induced only marginal or no proliferation
of MBP(87–99)-specific LN T cells.
 
Reactivation of Viral Peptide–specific T Cells with the MBP
Peptide Results in Increased Cross-reactivity in the T Cell Popu-
lation and Clinical Disease.
 
After testing the ability of viral
peptides to activate MBP(87–99)-specific T cells, we per-
formed the reverse experiment. SJL mice were immunized
with the papillomavirus peptide and tested for proliferation
to the MBP peptide in vitro (Fig. 1 
 
A
 
). LN cells from mice
primed with the papillomavirus peptide showed strong re-
sponses towards the viral peptide, but only a minimal re-
sponse to MBP(87–99). Stimulating the papillomavirus
peptide–specific LN cells once in vitro with moderate to
high doses of the same viral peptide (10–50 
 
m
 
g/ml) in-
creased the proliferative responses (upon restimulation 2
wk later) to the papillomavirus peptide, but it diminished
the response to MBP (Fig. 1 
 
B
 
). When we transferred such
a population of cells into naive SJL mice, there was almost
no clinical effect (Table 2, 
 
top
 
). Table 2 summarizes results
from independent adoptive transfer experiments using dif-
ferent short-term T cell lines.
Based on the hypothesis that only a subpopulation of the
T cells specific for the papillomavirus peptide could recog-
nize MBP(87–99) and vice versa, we decided to expand the
cross-reactive population by stimulating with the cross-
reactive instead of the priming antigen. LN cells from mice
primed with the viral peptide were stimulated in vitro with
50 
 
m
 
g/ml of the autoantigen MBP. 2 wk after in vitro
stimulation, a proliferation assay was performed which
demonstrated a marked increase in cross-reactivity (Fig. 1
 
C
 
). Interestingly, stimulation with MBP apparently selected
a subpopulation of viral peptide–specific cells that not only
 
Table 1.
 
Screening of a Panel of Viral and Bacterial Potential Mimicry Peptides for Their Ability to Stimulate LN Cells from SJL Mice 
Immunized with Peptide MBP(87–99)
 
Peptide Pathogen Sequence SImax
 
*
 
Cmax
 
‡
 
MBP(83–100)
 
ENPVVHFFKNIVTPRTPP
 
35.6 50
MBP(87–99)
 
VHFFKNIVTPRTP
 
43.8 100
Group 1. Peptides that matched the recognition motif for human MBP(85–99) specific T cell clones.
 
pHPV-7 Human papillomavirus 7
 
IGGRVHFFKDISPIASSE
 
15.2 100
8.5 50
6.6 10
3.6 1
2.4 0.1
 
19 Human CMV
 
VVALVNFLRHLTQKP
 
,
 
1.5
 
2
 
29 EBV
 
TGGVYHFVKKEAFNT
 
1.8 100
34 Lymphocytic choriomeningitis virus
 
ISIFLHFVRIPTHRH
 
,
 
1.5
 
2
 
41 Adenovirus 12
 
DFEVVTFLKDVLPEF
 
2.1 60
43 Coxsackie virus A9
 
TLMVIPFVKLDYADT
 
,
 
1.5
 
2
 
52 Influenza A
 
YRNLVWFIKKNTRYP
 
,
 
1.5 2
70 Pseudomonas DRLLMLFAKDVVSRN ,1.5 2
140 HIV RQTALFLLKLAARWP ,1.5 2
149 Herpes simplex GGRRLFFVKAHVRES ,1.5 2
180 Reovirus MARAAFLFKTVGFGG ,1.5 2
186 Human respiratory syncytium virus HSFKLWFLKRLNVAE ,1.5 2
193 Human astrovirus QITSIFLIKPLADFK ,1.5 2
Group 2. Peptides that matched the recognition motif for MBP(85–99) specific autoantibodies from MS patients.
B2 Human papillomavirus 13 IGGRVHFFKDISPIS 2.8 35
B3 Human papillomavirus 40 IGGRVHFFRDISPIG ,1.5 2
B4 Human papillomavirus 32 IGSRVHFFHDISPIT ,1.5 2
pEBV EBV RAHPVYFFKSACPPA 16.9 50
20.8 35
15.6 3.5
7.4 0.35
(continued)1729 Ufret-Vincenty et al.
Figure 1. Stimulation with MBP, but not
with moderate doses of papillomavirus pep-
tide, selects a highly cross-reactive subpopu-
lation of viral peptide–specific T cells. Pro-
liferative responses of (A) LN cells or (B and
C) T cell lines from SJL mice immunized
with 200 mg/mouse of papillomavirus pep-
tide in CFA. (A) Papillomavirus peptide–
specific LN cells are able to respond, but
only poorly to the self-antigen MBP(87–
99). In vitro proliferative responses are
shown for (B) a short-term T cell line estab-
lished by stimulating viral peptide–primed
LN cells once with 10 mg/ml pHPV-7, and
(C) a short-term T cell line established by
stimulating viral peptide–primed LN cells
once with 50 mg/ml MBP. Values represent
mean stimulation indices (6 SD) for tripli-
cate wells.
showed an increased response to the self-antigen (MBP),
but also responded optimally to very low concentrations of
the cognate viral peptide (Fig. 1 C).
Since it has been shown that the ability of T cells to re-
spond in vitro does not always correlate with an in vivo ef-
fect (42, 43), it was important to test the encephalitogenic
potential of the cross-stimulated cells. SJL mice were im-
munized with either MBP in CFA, papillomavirus peptide
in CFA, or CFA alone. 10 d later, the draining LNs were
collected. The cells were stimulated with 50 mg/ml of
Table 1. (continued)
Peptide Pathogen Sequence SImax* Cmax‡
pCMV Human CMV DRHPVYFFKSACPPN 17.5 100
26.6 50
18.5 35
9.3 3.5
1.5 0.35
B7 Dhori virus SDDFIHFFKAKSYDD ,1.5 2
B8 HSV-1 GGRRLFFVKAHVRES ,1.5 2
B9 EBV TGGVYHFVKKHVHES ,1.5 2
B10 Influenza A virus KDMTKEFFKNKSETW ,1.5 2
B11 Human herpes virus 4 VSGFISFFKNPFGGM 1.5 2
B12 Hepatitis A virus EVKPASFFKNPHNDM ,1.5 2
B13 Human adenovirus LATYHIFFKNQRIPL 4.4 50
B14 Streptococcus agalactiae RNIGYIFFKNSTIDI 2.5 100
B15 Bacillus subtilis RKVVTDFFKNIPQRI ,1.5 2
B16 Bacillus subtilis KGTIYTFFKNKEELF ,1.5 2
B17 Bacillus thuringiensis PAPADLFFKNADINV ,1.5 2
B18 Clostridium cellulare CDAISNFFKNIGYAN 7.8 100
B19 Vibrio anguillarum ELLHQRFFKNVESTP 4.5 100
B20 Pseudomonas aeruginosa LEIIEEFFKNKSGLK ,1.5 2
B21 Escherichia coli LLSAISFFKNTHDFI ,1.5 2
B22 Staphylococcus GIDFDKFFKNRIDTF ,1.5 2
B23 Streptococcus equisimilis RNKIRQFFKNQDKEL ,1.5 2
*Maximal stimulation index in a proliferation assay using LN cells from mice that had been immunized with 200 mg/mouse of peptide MBP(87–99).
Each peptide was tested in triplicate, at five different concentrations ranging from 0.1 to 100 mg/ml, in AIM-V medium.
‡Concentration of peptide (mg/ml) at which the maximal stimulation occurred. For the viral peptides pHPV-7, pEBV, and pCMV responses to sev-
eral doses of the antigens are shown.1730 Cross-reactive Viral Peptides in Experimental Encephalomyelitis
whole MBP for 4 d and transferred into naive animals. The
recipients of cells that were primed with the papillomavirus
peptide and stimulated in vitro with MBP developed se-
vere relapsing–remitting EAE with an incidence of 100%
(Fig. 2 A). The severity was comparable to that of mice re-
ceiving T cells which were both primed and stimulated
with MBP. Importantly, none of the animals that received
cells primed with CFA and cultured with 50 mg/ml of
MBP developed any sign of EAE, ruling out the possibility
that disease was due to in vitro priming by the autoantigen.
Papillomavirus peptide–primed T cells also induced severe
autoimmune disease when activated by the MBP(87–99)
peptide instead of the whole protein (not shown). Cells
primed with the immunogenic influenza virus peptide
NP(260–283), which is not cross-reactive with MBP(87–
99), did not induce disease when stimulated with the self-
peptide (not shown), demonstrating the specificity of the
phenomenon.
We also tested whether the induction of disease through
cross-stimulation was a bidirectional phenomenon, using T
cells that were primed with the MBP(87–99) peptide and
stimulated in vitro with the viral peptide (Fig. 2 B). These
cells also induced EAE. To exclude the possibility that dis-
ease was due to nonspecific bystander activation of T cells
(i.e., secretion of Th1 cytokines by surrounding cells), we
transferred T cells that had been primed with MBP(87–99)
and activated with the same strain of Mycobacterium tubercu-
losis (MT) as that contained in CFA (H37RA). This activa-
tion led to a strong proliferative response accompanied by
the secretion of high levels of TNF-a and IFN-g (data not
shown), but did not induce disease (Fig. 2 B).
Expansion of Virus-specific T Cells with Low Doses of Viral
Peptide Selects a Cross-reactive T Cell Population with a Th1
Phenotype. Since a subpopulation of papillomavirus-spe-
cific T cells that showed a high level of cross-reactivity to
MBP responded optimally to very low concentrations of
the cognate viral antigen (Fig. 1 C), we tested the hypothe-
sis that different doses of the papillomavirus peptide could
select subpopulations of viral peptide–specific T cells with
distinct response profiles to both the cognate viral peptide
and MBP(87–99). We collected LN cells from mice that
had been immunized with the viral peptide, split them into
Table 2. Passive Transfer of EAE with Cells that had been Primed with Either the Papillomavirus Peptide (pHPV-7), MBP(87–99), or MBP 
and Activated with the Specified Dose of the Priming Antigen
Immunization
In vitro
stimulation Dose
Incidence
of EAE
No. of
stimulations
Cells (/107)
transferred
Maximal
EAE score*
Day of
onset*
mg/ml
High antigen dose experiments
MBP(87–99) MBP(87–99) 10 3/4 1 6,6,6,6 3,3,2,0 ,9,,9,,9,2
pHPV-7 pHPV-7 10 0/4 1 6,6,6,6 0,0,0,0 2
MBP MBP 25 2/2 1 6,6 2,3 8,8
PHPV-7 pHPV-7 10 0/5 1 6,6,6,6,6 0,0,0,0,0 2
MBP(87–99) MBP(87–99) 10 4/4 1 10,10,10,10 3,3,3,3 7,7,8,8
pHPV-7 pHPV-7 50 1/6 1 10,10,10 1,0,0 9,2,2,
10,10,10 0,0,0 2,2,2
MBP(87–99) MBP(87–99) 10 2/3 3 2 4,4,0 7,7,0
pHPV-7 pHPV-7 10 0/3 3 2 0,0,0 2
Low antigen dose experiments
pHPV-7 pHPV-7 0.05 5/6 2 3 (1),‡ 0.6§ 2,3 7,6
2 3,3 (4)§ 2,1.5 6,7
5 3,3 2,0 8,2
pHPV-7 pHPV-7 0.05 4/5 2 3,3,0.8 2.5,2.5,0 7,7,2
2 3 (10),§ 1§ 3,2 6,7
pHPV-7 pHPV-7 0.05 4/4 2 3 (12),3,3,3 2.5,2.5,2,2 7,7,7,7
pHPV-7 pHPV-7 0.05 2/3 2 3 (16),3,3 2,1,0 8,8,2
pHPV-7 pHPV-7 0.05 4/4 2 4,4,4,4 5,3,3,2 6,6,6,8
MBP(87–99) MBP(87–99) 0.05 4/4 2 3,3,3,3 3,2.5,2.5,2.5 5,5,6,6
MBP(87–99) MBP(87–99) 10 4/4 2 3,3,3,3 5,5,5,4 5,5,5,5
*Data for individual mice are separated by commas.
‡Numbers in parenthesis relate to histopathological samples (see Fig. 5).
§Enriched for T cells at the LN cell stage as described in Materials and Methods.1731 Ufret-Vincenty et al.
five groups, and stimulated each group with a different
dose of viral peptide (0.004, 0.05, 0.4, 10, or 80 mg/ml). 2
wk later, the proliferative responses of the resulting popula-
tions of cells to the papillomavirus peptide and MBP(87–
99) were analyzed (Fig. 3 A). It was evident that the lower
doses of the viral peptide (0.004–0.4 mg/ml) were selecting
a population of cells that responded better to the autoanti-
gen MBP(87–99) than higher doses (10 and 80 mg/ml).
The same result was obtained in five different experiments
in which low (0.05 mg/ml; Fig. 3 B) versus moderate (10
mg/ml, which is the standard dose used for stimulation of
lines with encephalitogenic peptides; Fig. 3 C) doses of vi-
ral peptide were compared. Interestingly, the T cell popu-
lations expanded by low doses of the papillomavirus pep-
tide also showed a higher degree of cross-reactivity to the
EBV peptide (Fig. 3, B and C) and to a peptide from adeno-
virus (peptide 41, data not shown).
T cell lines (Table 3) specific for the papillomavirus pep-
tide or peptide MBP(87–99) were tested for cytokine pro-
duction upon stimulation with different doses of the prim-
ing antigen. The viral peptide–specific T cells had a similar
pattern of cytokine secretion to that of MBP(87–99)-spe-
cific cells (Th1 skewed). However, papillomavirus peptide–
specific T cells secreted higher levels of TNF-a and IFN-g
than the MBP(87–99)-specific T cells when stimulated
with similar doses of the priming antigen (Table 3). Even
Figure 2. Cross-stimulation of viral peptide–primed LN cells with the
self-antigen (and vice versa) can select and activate potently encephalito-
genic cells. Mice were immunized with an emulsion in CFA containing
either no additional antigen, 400 mg of MBP, 200 mg of pHPV-7 or
MBP(87–99), or 5 mg of NP(260–83) (not shown). 10 d later, LN cells
were collected and stimulated with either (A) 50 mg/ml of MBP or (B) 10
mg/ml of the specified antigens. 4 d after stimulation, 108 cells were in-
jected intraperitoneally into each naive recipient.
Figure 3. Very low doses of human papilloma virus peptide (0.004–0.4
mg/ml) select cross-reactive subpopulations of cells compared with mod-
erate and high doses (10–100 mg/ml). (A) LN cells from mice that had
been immunized with 200 mg/mouse of papillomavirus peptide were split
into five groups and stimulated with various concentrations of the same
viral peptide. Each curve represents the response to peptide MBP(87–99)
by a particular T cell line. The maximal stimulation index in response to
the papilloma virus peptide by each T cell line (SImax) and the concentra-
tion at which it occurred (Cmax) are shown. A separate experiment in
which papilloma virus peptide–primed LN cells were stimulated with ei-
ther (B) 0.05 mg/ml or (C) 10 mg/ml of the same viral peptide is also
shown. In a similar approach, EBV peptide–primed LN cells were stimu-
lated with either (D) 0.1 mg/ml or (E) 10 mg/ml of EBV peptide. Con-
trary to the papillomavirus peptide, the EBV peptide was not able to
expand an autoreactive population of EBV peptide–specific cells. The
short-term T cell lines generated by these means were tested (A–E) in
standard proliferation assays, performed 14 d after the first activation. The
viral peptide was not toxic at 10 mg/ml; when papillomavirus-specific T
cells selected by one in vitro stimulation with 10 mg/ml of the viral pep-
tide were stimulated for a second time in vitro using the same dose of vi-
ral peptide, the cell number increased to 145–180% of the original value
in 3 d. If papillomavirus-specific T cells selected with 0.05 mg/ml were
stimulated a second time with 0.05 mg/ml of viral peptide, the cell yield
3 d later was 160–170% of the initial value.1732 Cross-reactive Viral Peptides in Experimental Encephalomyelitis
low doses of the viral peptide led to this Th1 phenotype
(including low production of IL-10). Table 3 shows cyto-
kine levels produced by short-term T cell lines from one
representative experiment out of three independent experi-
ments performed using different T cell lines in each experi-
ment.
Specificity and Degeneracy of Antigen Recognition by T Cell
Clones from SJL Mice. To demonstrate recognition of dif-
ferent peptides by the same T cell, T cell clones were
raised. Fig. 4 shows representative examples of responses by
a panel of three clones specific for human papillomavirus
peptide (pHPV-7) that were tested for recognition of two
MBP peptides (p87–99 and p83–100) and two virus-
derived peptides (pHPV-7 and pEBV). The clones (limit-
ing dilution approach, 0.5 cells/well) were generated from
papillomavirus peptide–primed LN cells that were only
stimulated with the papillomavirus peptide at low doses
(0.01–0.05 mg/ml) during in vitro expansion. Clones RU-
1.01 and RU-4.01 proliferated to both the papillomavirus
peptide and MBP(87–99), whereas clone RU-1.05 re-
sponded only to the papillomavirus peptide (in total, 3 out
of 11 clones raised under similar conditions showed cross-
reactivity to the MBP peptides).
Low Dose Viral Peptide–specific Cells Induce EAE. Based
on these data, we reasoned that low concentrations of the
viral peptide may select a subpopulation of T cells with a
high encephalitogenic potential. After stimulation of LN
cells specific for the papillomavirus peptide with 0.05 mg/
ml of the same peptide, the cells were cultured for 2 wk,
then reactivated with the same antigen/dose (Table 2, bot-
tom). 3 d later, naive animals were injected intraperitoneally
with 3 3 107 cells/mouse and observed for the develop-
ment of clinical signs of EAE (Table 2, summary of results
from independent adoptive transfer experiments using dif-
ferent short-term T cell lines). The disease induced by
these papillomavirus-specific cells which had been stimu-
lated with low doses of their cognate antigen (and never
exposed to the self-antigen in vitro) was consistently early
in onset, high in incidence, and moderate to severe in qual-
ity (Table 2, bottom). EAE could be transferred by papillo-
mavirus-specific T cell lines that were established after T
cell enrichment of LN cells to a level of .97% purity.
FACSÒ analysis of the T cell lines generated after two in
vitro stimulations with low doses of the papillomavirus
peptide revealed that .97% of the T cells were CD41 (data
not shown). Disease could be transferred, although with
decreasing incidence, even after five in vitro stimulations
with 0.05 mg/ml of papillomavirus peptide.
The papillomavirus peptide was also tested for active in-
duction of EAE (as described in reference 44) over a dose
Table 3. Cytokine Production at 48 h by Short-term T Cell Lines Stimulated with Different Doses of the Priming Antigen
Sample Cytokine concentration
Immunization First stimulation Second stimulation TNF-a IFN-g IL-4 IL-10
mg/ml mg/ml pg/ml
MBP(87–99) 10 No Ag 0 1,605 6 26 0 0
10 25,368 6 434 9,508 6 116 77 6 5 3,693 6 222
pHPV-7 0.05 No Ag 0 97 0 0
0.05 6,509 6 251 15,768 6 84 0 468 6 70
10 No Ag 0 0 0 0
10 45,079 6 405 18,595 6 3,570 0 1,464 6 104
Representative data (6 SD) from three independent experiments with different T cell lines in each experimental series.
Figure 4. T cell clones specific for the
human papilloma virus peptide recognize
the self-antigens MBP(87–99) and
MBP(83–100). T cell clones were generated
from HPV-specific T cell lines which had
been expanded with low doses of the same
viral peptide. These clones were tested for
their ability to proliferate in vitro to the self-
peptides MBP(87–99) and MBP(83–100)
and the viral peptides from HPV and EBV.
T cell clones were incubated with irradiated
splenocytes and various concentrations of
the peptides in EAE medium. The values
correspond to mean stimulation indices
from triplicate wells.1733 Ufret-Vincenty et al.
range of 200 mg to 2 mg of peptide per mouse. Two out of
six mice immunized with 2 mg of the papillomavirus pep-
tide developed mild to moderate disease. Clinical onset
(day 12) and maximal severity (grade 2 in both mice) of
disease were comparable to MBP-induced EAE, whereas
disease duration was only 2–3 d. No signs of clinical disease
were observed in nine mice immunized with 200 mg of the
papillomavirus peptide. Results obtained in vitro and in
adoptive transfer experiments suggest that multiple expo-
sures to low doses of the viral peptide are more effective in
selecting an autoreactive T cell population.
Histological Features of Disease Induced by T Cell Lines Spe-
cific for the Papillomavirus Peptide. Histological examination
demonstrated that disease induced by T cell lines specific
for the papillomavirus peptide and the MBP(87–99) pep-
tide was indistinguishable when animals with similar clini-
cal severity were compared. Several lesion types could be
identified within individual mice in both groups. Some
lesions consisted mainly of lymphocytic infiltrates (Fig. 5
A). These infiltrates typically occurred either in the
meninges or in very close proximity to a blood vessel, and
were usually not accompanied by significant demyelina-
tion. Lesions containing mixed cellular infiltrates in which
either macrophages (Fig. 5 B, and central lesion in Fig. 5
D) or polymorphonuclear cells (Fig. 5 C, and subpial lesion
in Fig. 5 D) predominated commonly showed inflamma-
tory cells infiltrating deep into the parenchyma and were
accompanied by myelin destruction as demonstrated by
luxol fast blue stains (Fig. 5 E). In these lesions, demyelina-
tion was either limited to the area of infiltration or ex-
tended beyond the infiltrate. These histopathological find-
ings are akin to those described by Fallis et al. (45) and are
considered characteristic of EAE.
Reactivation of Virus-specific T Cells with an Unrelated Viral
Peptide Renders them Encephalitogenic. The observation that
the EBV peptide could reactivate both MBP peptide or
papillomavirus-specific T cells (Table 1, and Fig. 3 B) was
further analyzed. In contrast to the papillomavirus peptide,
cross-reactivity with the EBV peptide was largely unidirec-
tional. When SJL mice were immunized with the EBV
peptide, LN cells showed very low responses to MBP(87–
99), much lower than those from papillomavirus peptide–
Figure 5. Representative photomicrographs of EAE histopathology in SJL mice transferred with papillomavirus peptide–specific T cells. (A) A large
chronic inflammatory (lymphocytic) infiltrate is identified in the cortical meninges (original magnification: 320; H&E). (B) A chronic inflammatory in-
filtrate of the spinal cord deep white matter consisting primarily of macrophages (arrows; original magnification: 340; H&E). (C) An acute inflammatory
infiltrate of the spinal cord subpial white matter consisting of a mixture of polymorphonuclear neutrophils, lymphocytes, and macrophages (original mag-
nification: 340; H&E). (D) A low power view of a longitudinal section of spinal cord demonstrating both acute (as in C) and chronic (as in B) infiltrates
(original magnification: 35; H&E). (E) Luxol fast blue histochemical stain reveals the loss of myelin in an adjacent section of spinal cord (original magni-
fication: 35).1734 Cross-reactive Viral Peptides in Experimental Encephalomyelitis
primed LN cells. Furthermore, neither low (0.1 mg/ml)
nor moderate (10 mg/ml) doses of pEBV could expand a
subpopulation of T cells with significant cross-reactivity to
MBP(87–99) or MBP(83–100) (Fig. 3, D and E). Transfer
of EBV peptide–specific T cells that had been stimulated
twice in vitro with either 0.1 or 10 mg/ml of EBV peptide
did not induce disease (data not shown).
Since we observed that papillomavirus-specific cells that
had been stimulated with low doses of papillomavirus pep-
tide showed an increased response to the EBV peptide, we
designed the following experiment (Fig. 6). 2 wk after an
in vitro stimulation of papillomavirus-specific LN cells with
0.05 mg/ml of papillomavirus peptide (first in vitro activa-
tion), the resulting T cell line was divided into four differ-
ent groups and reactivated with either 0.002 mg/ml of
staphylococcal enterotoxin A (SEA), 0.05 mg/ml of papil-
lomavirus peptide, 50 mg/ml of MBP(87–99), or 50 mg/ml
of the EBV peptide. Since activation of T cells is required
for their extravasation into the CNS (46, 47) and induction
of EAE (48, 49), we tested whether nonantigen-specific
stimulation of T cells by the superantigen (SEA) was suffi-
cient to reactivate encephalitogenic T cells through by-
stander activation. Although the given dose of SEA in-
duced a powerful activation of at least a subpopulation of T
cells, as measured by proliferation and the secretion of the
Th1 cytokines IFN-g and TNF-a, the resulting population
of cells did not induce disease when transferred 72 h after
activation (SEA has been reported to activate T cells ex-
pressing a Vb3 or Vb17 TCR rearrangement in the SJL
mouse [50]). In contrast, T cells activated with either the
papillomavirus peptide or MBP(87–99) induced disease.
Interestingly, the cells reactivated with the EBV peptide in-
duced EAE with a similar incidence (2/2) and severity
(mean maximal clinical severity of 2.5 6 0.7) as the other
two groups. This was the case even when a low dose of the
EBV was used (Fig. 6 B).
In Vivo Survival of Viral Peptide–specific Cells that Recognize
the Self-antigen. For T cells selected and expanded by a vi-
ral antigen to induce autoimmune disease after a second ex-
posure to the same or a different viral antigen, they need to
survive in vivo for a prolonged time after the first activa-
tion. To examine this possibility, we transferred naive mice
with encephalitogenic T cell lines that had been generated
either by stimulation of papillomavirus peptide (pHPV-7)-
specific LN cells with 0.05 mg/ml (Fig. 7 A) or 0.07 mg/ml
(Fig. 7 B) of pHPV-7 (cells used in B were coming from
different LN cells than those in A), or by stimulation of
MBP(87–99)-specific LN cells with 10 mg/ml of the same
MBP peptide (Fig. 7 C). The proliferative responses to var-
ious self- and viral peptides of the resulting T cell lines
were assayed 2 wk after the first stimulation (Fig. 7, A1,
B1, and C1). At the same time, the T cell lines were reacti-
vated for transfer into naive animals using the same antigen
and dose as for the first stimulation. 3 d after activation, 4 3
107 cells were transferred intraperitoneally into each naive
recipient. 47 d (Fig. 7, A2 and C2) or 79 d (Fig. 7 B2) after
transfer, the animals were killed and the splenocytes tested
in a proliferation assay. Surprisingly, not only was it clear
that the cells survived in vivo even after .11 wk, but it
also seemed that the interactions within the animal had se-
lected a highly self-reactive T cell population from the pap-
illomavirus-specific cells (Fig. 7, A2 and B2). These cells
responded vigorously to both the papillomavirus peptide
and the EBV peptide.
Discussion
To advance our understanding of the potential role of
microbial antigens in the induction of autoimmunity, it is
important to consider the complex interactions between
pathogen-derived antigens and cross-reactive T cells in
polyclonal T cell populations with multiple specificities. In
this study, we focused on LN cell populations, short-term
T cell lines, and T cell clones. We began by screening
pathogen-derived peptides, testing them for their ability to
activate populations of MBP(87–99)-primed LN cells in
vitro. Despite the lack of a well-defined MHC/TCR rec-
ognition motif for SJL mice, we identified three viral pep-
tides that showed significant cross-reactivity (19) with
MBP(87–99). Immunization with one of these peptides,
from the human papillomavirus L2 capsid protein, resulted
in a T cell population that showed a vigorous response
Figure 6. An unrelated viral peptide from EBV activates papillomavirus
peptide–specific cells resulting in EAE. A short-term T cell line was gen-
erated by stimulating papillomavirus–primed LN cells with 0.05 mg/ml of
the same viral peptide. 2 wk later, the resulting cells were split into four
groups and stimulated with 0.05 mg/ml of papillomavirus peptide, 50 mg/
ml MBP(87–99), 50 mg/ml of the EBV peptide, or 0.002 mg/ml of SEA.
Naive mice were transferred intraperitoneally with either 3 3 107 cells
(two animals per group for the papillomavirus–, MBP(87–99)-, and EBV
peptide–activated cells) or 6 3 107 cells (two animals for the SEA-acti-
vated cells).1735 Ufret-Vincenty et al.
to the viral peptide and significant cross-reactivity to
MBP(87–99). Stimulation of LN cells from mice immu-
nized with the papillomavirus peptide with different doses
of the same viral peptide appeared to select different T cell
subpopulations. The cells resulting from stimulation with
moderate to high doses of the papillomavirus peptide (10–
80 mg/ml) responded optimally to high doses of papilloma-
virus peptide and showed very low responses to MBP(87–
99) and the EBV peptide. In contrast, stimulation with low
doses of papillomavirus peptide (0.004–0.4 mg/ml) selected
cells that responded optimally to low doses of the viral
peptide and in addition showed an increased response
to MBP(87–99) and to other cross-reactive viral peptides
(EBV peptide and peptide 41). This “low dose” population
of cells induced severe EAE at a high incidence. Moreover,
the highly promiscuous population of cells selected by low
doses of the papillomavirus peptide, different from that se-
lected by high doses, could also be reactivated and rendered
encephalitogenic by an unrelated EBV peptide. Of note,
only four amino acids (V-FFK) were conserved among the
papillomavirus peptide, the EBV peptide, and the MBP
peptide. The low doses of viral peptide apparently selected a
population of T cells with higher affinity for the I-As/papil-
lomavirus peptide complex. High affinity for the low dose
selecting viral antigen may explain the increased cross-reac-
tivity of this T cell population with MBP(87–99) and the
unrelated EBV peptide, since T cells with a higher affinity
for their MHC/peptide ligands may tolerate nonconserva-
tive substitutions of the peptide. Interestingly, similar obser-
vations have been made for human MBP-specific T cell
clones (19). In addition, it was shown that antibodies with
higher affinity for their cognate ligand display a broader
cross-reactivity to other antigens (51). We conclude that
cross-reactivity and pathogenicity of selected T cell popula-
tions are dependent on the dose of the selecting antigen.
The papillomavirus peptide was previously found to acti-
vate an MBP-specific HLA-DQ1–restricted T cell clone
from an MS patient; this T cell clone recognized four mi-
crobial peptides (derived from HSV, adenovirus type 12,
human papillomavirus type 7, and Pseudomonas aeruginosa).
The papillomavirus peptide was an effective stimulator of
this T cell clone (background proliferation 1,059 6 48 cpm,
MBP(85-99) 11,661 6 468 cpm, papillomavirus peptide
7,675 6 10 cpm; our unpublished observations); among the
other peptides, the adenovirus peptide induced the strongest
stimulation of the T cell clone. Since murine I-A molecules
are the homologues of HLA-DQ, these peptides were can-
didates for the induction of EAE in SJL mice. Of the four
peptides tested, the papillomavirus peptide induced strong
stimulation of MBP(87–99)-specific T cells, whereas the ad-
enovirus peptide showed only a low level of cross-reactiv-
ity. These results indicate that there are similarities, as well
as differences, in the specificity of human and murine TCRs
specific for this immunodominant MBP peptide.
The concept that T cell population dynamics are impor-
tant in the development of an autoimmune process is sup-
ported by another set of results. Different pathogen-derived
antigens, and even different doses of the same antigen,
might contribute in diverse ways to the development of
autoimmunity by molecular mimicry, depending on their
effect on self-reactive populations of T cells: (a) some viral
peptides may prime and, on their own, activate T cells that
will induce autoimmunity; (b) particular combinations of
antigen and dose may predominantly expand and/or main-
tain a population of self-reactive memory T cells. Continu-
ous or recurrent exposure to antigenic stimulation either by
the cognate peptide or a cross-reactive peptide may be nec-
essary to maintain T cell memory (52–54); and (c) some vi-
ral peptides (e.g., EBV peptide) which are unable to select
and expand a self-reactive population of T cells on their
own (because they preferentially expand a noncross-reac-
tive population of viral peptide–specific cells) may still be
capable of activating a self-reactive population that had al-
ready been selected and expanded by another viral peptide
(Fig. 6) or the self-antigen. Certain combinations of anti-
Figure 7. Survival of viral peptide–specific encephalitogenic T cells in
vivo. Proliferative responses of (A1, B1, and C1) T cell lines at the time
of the second stimulation, and of splenocytes from mice transferred (A2
and C2) 47 d or (B2) 79 d earlier with the cells resulting from the second
activation of those T cell lines. Panels represent the in vitro responses of
(A1 and B1) two different papillomavirus-specific T cell lines; (A2 and
B2) the splenocytes from individual mice transferred with the same T cell
lines after reactivation with (A2) 0.05 mg/ml of pHPV-7 (representative
of three mice) or with (B2) 0.07 mg/ml of pHPV-7 (representative of
three mice); (C1) the MBP(87–99)-specific T cell line; and (C2) the sple-
nocytes from a mouse (representative of two mice) transferred with the
same line after stimulation with 10 mg/ml of MBP(87–99).1736 Cross-reactive Viral Peptides in Experimental Encephalomyelitis
gen and dose (low doses of papillomavirus peptide) might
preferentially expand a subpopulation of virus-specific T
cells that show cross-reactivity to both the self-antigen and
other viral antigens. The result would be an increase in the
population of self-reactive cells that is available for activa-
tion either by the original viral antigen, or by a different
antigen (e.g., EBV peptide).
In that view, the observation that viral peptide–specific
cells survived in vivo for a long time and were enriched for
recognition of the self-antigen and the unrelated EBV pep-
tide (Fig. 7) was particularly interesting. In our model, in
vivo survival of an autoreactive population of viral peptide–
specific cells was observed in the absence of the cognate vi-
ral antigen in the animal. These results led us to speculate
that exposure to the self-antigen in vivo (compare to expo-
sure to self-antigen in vitro, Fig. 1 C) might again reshape
the viral peptide–specific T cell population in a manner
that would increase its potential for both (a) reactivation by
a second exposure to the same or a different viral peptide
and (b) induction of autoimmune disease.
Although it is not possible to draw conclusions about the
role of a specific pathogen in triggering a particular human
autoimmune disease based on studies in this animal model,
our data suggest a role of molecular mimicry in the induction
of T cell–mediated autoimmunity. Activation of self-reactive
T cells by viral antigens could be relevant in two important
steps in the development of inflammatory CNS diseases: (a)
enhanced interaction with and transmigration through the
blood–brain barrier (46, 47), and (b) facilitated reactivation of
pathogenic cells by the self-antigen upon encounter in the
CNS due to reduced requirements for costimulation of acti-
vated T cells (55–61). The fact that it has not been possible to
identify a single pathogen as a culprit of MS may indicate that
(sub)clinical infections may be involved. Furthermore, given
the ability of viral antigen–primed autoreactive T cells to sur-
vive in vivo, it is possible to envision that a series of infections
with different pathogens may be responsible for selection,
maintenance, and/or expansion of a cross-reactive and patho-
genic subpopulation of T cells.
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